[Animal experiments on the nephrotoxicity, pharmacokinetics and therapeutic efficacy of dibekacin].
Nephrotoxicity, pharmacokinetics, and therapeutic efficacy of 3',4'-dideoxykanamycin (dibekacin), a semisynthetic aminoglycoside, were evaluated in rats. As with other aminoglycosides, therapy with dibekacin led to an increased urinary cell and malic-dehydrogenase excretion. The lowest dose resulting in an increased urinary cell excretion was 2.5 mg/kg/d. Serum levels of dibekacin after i.m. injection of 5 mg/kg were similar to those of other aminoglycosides. The kidneys accumulated high amounts of dibekacin, and eliminated it with a half-life of about 7 days. After repetitive dosing a distinct tendency to accumulation (highest renal concentration: 330 microgram/g) could be detected. Experimental chemotherapy of the chronic estrogen induced pyelonephritis revealed that dibekacin and sisomicin fed to significant reductions of renal bacterial counts at a dosage of 2 x 5 mg/kg/d for 7 days. A dosage of 2 x 2.5 mg/kg/d diminished the effectiveness of dibekacin distinctly, that of sisomicin only slightly.
D000818:Animals; D003982:Dibekacin / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D007612:Kanamycin / Q000031:analogs & derivatives*; D007674:Kidney Diseases / Q000139:chemically induced; D007700:Kinetics; D008291:Malate Dehydrogenase / Q000378:metabolism; D051381:Rats; D012853:Sisomicin / Q000494:pharmacology
D003982:Dibekacin; D007612:Kanamycin; D008291:Malate Dehydrogenase; D012853:Sisomicin
Tierexperimentelle Studien zur Nierenverträglichkeit, Pharmakokinetik und therapeutischen Effektivität von Dibekacin.